ClinicalTrials.gov NCT05934110 Wilding JPH, et al
This is certainly the case when it comes to compounded semaglutide, a critical medication addressing this nations obesity crisis
Hepatology 45 (5), 11641171
Real GLP-1 medications produce dramatic, clinically significant weight loss
In an associated Commentary titled Thyroid Cancer Risk with GLP-1 Receptor Agonists: Evidence, Knowledge Gaps, and the Path Forward, Juan Brito, MD , from the Mayo Clinic, and coauthors, stated the following: this study stands out for its large scale and robust methodology
A patient who might lose 30 pounds on semaglutide could expect to lose approximately 45 pounds on tirzepatide and potentially 60 pounds or more on Retatrutide, assuming similar starting weights and treatment adherence